Natural History of Multiple Sclerosis: Long-Term Prognostic Factors

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 293-308

  Renoux, Christel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Disability; Epidemiology; Multiple sclerosis; Prognosis; Prognostic factors

Indexed keywords

DISABILITY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HUMAN; MULTIPLE SCLEROSIS; ONSET AGE; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

AGE OF ONSET; DISABILITY EVALUATION; DISEASE PROGRESSION; ENVIRONMENT; HUMANS; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 79952849738     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.01.006     Document Type: Review

References (92)

1. Hoffmann S., Tittgemeyer M., von Cramon D.Y. Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007, 20:275-280.
2. Chiaravalloti N.D., DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008, 7:1139-1151.
3. Peyser J.M., Rao S.M., LaRocca N.G., et al. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol 1990, 47:94-97.
4. Rao S.M., Leo G.J., Bernardin L., et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991, 41:685-691.
5. Kurtzke J.F. On the evaluation of disability in multiple sclerosis. Neurology 1961, 11:686-694.
6. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
7. Sharrack B., Hughes R.A. Clinical scales for multiple sclerosis. J Neurol Sci 1996, 135:1-9.
8. Thompson A.J., Hobart J.C. Multiple sclerosis: assessment of disability and disability scales. J Neurol 1998, 245:189-196.
9. Confavreux C., Compston A. The natural history of multiple sclerosis. McAlpine's multiple slerosis 2006, 183-272. Churchill Livingstone Elsevier, London. 4th edition. A. Compston (Ed.).
10. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt 1):133-146.
11. Confavreux C., Vukusic S., Moreau T., et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430-1438.
12. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
13. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116(Pt 1):117-134.
14. Pittock S.J., Mayr W.T., McClelland R.L., et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004, 62:601-606.
15. Tremlett H., Paty D., Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006, 66:172-177.
16. Debouverie M., Pittion-Vouyovitch S., Louis S., et al. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008, 15:916-921.
17. Confavreux C. Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler 2008, 14:289-291.
18. Cree B.A., Khan O., Bourdette D., et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004, 63:2039-2045.
19. Kaufman M.D., Johnson S.K., Moyer D., et al. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil 2003, 82:582-590.
20. Marrie R.A., Cutter G., Tyry T., et al. Does multiple sclerosis-associated disability differ between races?. Neurology 2006, 66:1235-1240.
21. Weinstock-Guttman B., Jacobs L.D., Brownscheidle C.M., et al. Multiple sclerosis characteristics in African American patients in the New York state multiple sclerosis consortium. Mult Scler 2003, 9:293-298.
22. Debouverie M., Lebrun C., Jeannin S., et al. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology 2007, 68:29-32.
23. Kantarci O., Siva A., Eraksoy M., et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998, 51:765-772.
24. Weinshenker B.G., Rice G.P., Noseworthy J.H., et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991, 114(Pt 2):1045-1056.
25. Amato M.P., Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci 2000, 21:S831-S838.
26. Eriksson M., Andersen O., Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003, 9:260-274.
27. Myhr K.M., Riise T., Vedeler C., et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001, 7:59-65.
28. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980, 103:281-300.
29. Confavreux C., Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006, 129:595-605.
30. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989, 112(Pt 6):1419-1428.
31. Tremlett H., Yousefi M., Devonshire V., et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009, 73:1616-1623.
32. Bergamaschi R., Berzuini C., Romani A., et al. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001, 189:13-21.
33. Tremlett H., Yinshan Z., Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008, 14:314-324.
34. Trojano M., Avolio C., Manzari C., et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995, 58:300-306.
35. Vukusic S., Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003, 206:135-137.
36. Cottrell D.A., Kremenchutzky M., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999, 122(Pt 4):625-639.
37. Koch M., Kingwell E., Rieckmann P., et al. The natural history of primary progressive multiple sclerosis. Neurology 2009, 73:1996-2002.
38. Andersson P.B., Waubant E., Gee L., et al. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 1999, 56:1138-1142.
39. Bergamaschi R., Quaglini S., Trojano M., et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007, 78:757-759.
40. de Groot V., Beckerman H., Uitdehaag B.M., et al. Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Arch Phys Med Rehabil 2009, 90:1478-1488.
41. Mandrioli J., Sola P., Bedin R., et al. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008, 255:1023-1031.
42. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
43. Vukusic S., Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007, 20:269-274.
44. Confavreux C., Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
45. Kremenchutzky M., Cottrell D., Rice G., et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999, 122(Pt 10):1941-1950.
46. Kremenchutzky M., Rice G.P., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594.
47. Trojano M., Liguori M., Bosco Z.G., et al. Age-related disability in multiple sclerosis. Ann Neurol 2002, 51:475-480.
48. Frischer J.M., Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
49. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
50. Barcellos L.F., Sawcer S., Ramsay P.P., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15:2813-2824.
51. Hensiek A.E., Sawcer S.J., Feakes R., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:184-187.
52. Masterman T., Ligers A., Olsson T., et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000, 48:211-219.
53. Smestad C., Brynedal B., Jonasdottir G., et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007, 14:835-840.
54. Chapman J., Vinokurov S., Achiron A., et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001, 56:312-316.
55. Evangelou N., Jackson M., Beeson D., et al. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999, 67:203-205.
56. Fazekas F., Strasser-Fuchs S., Kollegger H., et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001, 57:853-857.
57. Hogh P., Oturai A., Schreiber K., et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000, 6:226-230.
58. Pinholt M., Frederiksen J.L., Andersen P.S., et al. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult Scler 2005, 11:511-515.
59. Schmidt S., Barcellos L.F., DeSombre K., et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002, 70:708-717.
60. Kantarci O.H., Hebrink D.D., Achenbach S.J., et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004, 62:811-814.
61. Savettieri G., Andreoli V., Bonavita S., et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003, 250:1094-1098.
62. Burwick R.M., Ramsay P.P., Haines J.L., et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006, 66:1373-1383.
63. Masterman T., Zhang Z., Hellgren D., et al. APOE genotypes and disease severity in multiple sclerosis. Mult Scler 2002, 8:98-103.
64. Santos M., do Carmo C.M., Edite R.M., et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004, 10:153-157.
65. Van der Walt A., Stankovich J., Bahlo M., et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009, 73:1018-1025.
66. Weatherby S.J., Mann C.L., Davies M.B., et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000, 6:32-36.
67. Kantarci O.H., de A.M., Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002, 123:144-159.
68. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346:158-164.
69. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
70. Imrell K., Landtblom A.M., Hillert J., et al. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006, 67:1062-1064.
71. Siritho S., Freedman M.S. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009, 279:21-25.
72. Joseph F.G., Hirst C.L., Pickersgill T.P., et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009, 80:292-296.
73. Stendahl-Brodin L., Link H. Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1980, 43:102-105.
74. Zeman A.Z., Kidd D., McLean B.N., et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 60:27-30.
75. Imrell K., Greiner E., Hillert J., et al. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009, 210:128-130.
76. Villar L.M., Masjuan J., Gonzalez-Porque P., et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003, 53:222-226.
77. Villar L.M., Sadaba M.C., Roldan E., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
78. Confavreux C., Hutchinson M., Hours M.M., et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
79. Ghezzi A., Caputo D. Pregnancy: a factor influencing the course of multiple sclerosis?. Eur Neurol 1981, 20:115-117.
80. Poser S., Poser W. Multiple sclerosis and gestation. Neurology 1983, 33:1422-1427.
81. Roullet E., Verdier-Taillefer M.H., Amarenco P., et al. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 1993, 56:1062-1065.
82. Thompson D.S., Nelson L.M., Burns A., et al. The effects of pregnancy in multiple sclerosis: a retrospective study. Neurology 1986, 36:1097-1099.
83. Weinshenker B.G., Hader W., Carriere W., et al. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. Neurology 1989, 39:1438-1440.
84. D'hooghe M.B., Nagels G., Uitdehaag B.M. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010, 81:38-41.
85. Runmarker B., Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995, 118(Pt 1):253-261.
86. Verdru P., Theys P., D'hooghe M.B., et al. Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg 1994, 96:38-41.
87. Hernan M.A., Jick S.S., Logroscino G., et al. Cigarette smoking and the progression of multiple sclerosis. Brain 2005, 128:1461-1465.
88. Healy B.C., Ali E.N., Guttmann C.R., et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009, 66:858-864.
89. Pittas F., Ponsonby A.L., van der Mei I.A., et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009, 256:577-585.
90. Koch M., van H.A., Uyttenboogaart M., et al. Cigarette smoking and progression in multiple sclerosis. Neurology 2007, 69:1515-1520.
91. Renoux C., Vukusic S., Mikaeloff Y., et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007, 356:2603-2613.
92. Simone I.L., Carrara D., Tortorella C., et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002, 59:1922-1928.